Published in Br Heart J on May 01, 1993
The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart (2003) 1.63
Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart (2002) 1.41
Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart (1996) 1.21
NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart (2003) 1.13
Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations? Br Heart J (1993) 1.11
Prognostic value of B-type natriuretic peptide (BNP) and its potential role in guiding fluid therapy in critically ill septic patients. Scand J Trauma Resusc Emerg Med (2012) 0.97
Molecular cloning of hamster brain and atrial natriuretic peptide cDNAs. Cardiomyopathic hamsters are useful models for brain and atrial natriuretic peptides. J Clin Invest (1994) 0.93
Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol (2009) 0.87
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) (2016) 0.87
Changes in brain natriuretic peptide are correlated with changes in global end-diastolic volume index. J Thorac Dis (2013) 0.83
Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases. Heart Fail Rev (2010) 0.80
Association of E/E' and NT-proBNP with renal function in patients with essential hypertension. PLoS One (2013) 0.78
Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. BMJ (1999) 0.78
Novel strategies for the detection of systolic and diastolic heart failure. Curr Cardiol Rev (2009) 0.77
The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology. Biomark Insights (2007) 0.75
Outpatient management of heart failure. Heart Fail Rev (2003) 0.75
A new natriuretic peptide in porcine brain. Nature (1988) 4.22
Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest (1991) 3.70
Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science (1991) 2.25
Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man. J Clin Invest (1970) 2.18
Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 1.87
Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med (1986) 1.60
Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med (1990) 1.53
Plasma alpha natriuretic peptide in cardiac impairment. Br Med J (Clin Res Ed) (1986) 1.44
Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab (1993) 1.21
Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun (1989) 1.21
The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation (1986) 1.18
Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab (1986) 1.14
Radioimmunoassay for brain natriuretic peptide (BNP) detection of BNP in canine brain. Biochem Biophys Res Commun (1989) 0.93
Isolation and identification of a high molecular weight brain natriuretic peptide in porcine cardiac atrium. Biochem Biophys Res Commun (1988) 0.85
Sponsorship, authorship, and accountability. Lancet (2001) 7.10
Sponsorship, authorship, and accountability. N Engl J Med (2001) 6.20
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 6.01
Sponsorship, authorship and accountability. CMAJ (2001) 5.86
Unsatisfactory redefinition of myocardial infarction. Lancet (2001) 2.89
Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med (1974) 2.60
Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A (1982) 2.52
Management of raised blood pressure in New Zealand. N Z Med J (1993) 2.48
The Elag-Koln automatic blood pressure recorder. A clinical appraisal. Br Heart J (1977) 2.34
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 2.17
Management of raised blood pressure. N Z Med J (1994) 2.03
Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet (1985) 1.95
Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet (1973) 1.89
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) (1997) 1.73
Cardiogenic shock treated with infusion of dextrose solution. Am Heart J (1967) 1.69
Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br Med J (1977) 1.68
Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke (1991) 1.61
Diagnostic index for premyxoedema. Lancet (1973) 1.61
Clinical evaluation of perhexiline maleate in patients with angina pectoris. Br Med J (1971) 1.60
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. Br Heart J (1976) 1.59
B-type natriuretic peptide infusions in acute myocardial infarction. Heart (2007) 1.58
Liquorice toxicity and the renin-angiotensin-aldosterone axis in man. Br Med J (1977) 1.56
Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study. J Hum Hypertens (1989) 1.55
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol (2001) 1.54
Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem (2001) 1.51
Cough with angiotensin converting-enzyme inhibitors. N Z Med J (1987) 1.48
Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension. Lancet (1984) 1.48
Hypertension--still an important cause of heart failure? J Hum Hypertens (2005) 1.46
Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf) (1996) 1.45
The nature and prognosis of thyrotoxic heart disease. Q J Med (1985) 1.43
Radiofrequency ablation for common atrial flutter using an 8-mm tip catheter and up to 150 W. Europace (2005) 1.43
The management of mildly raised blood pressure in New Zealand: an alternative view. N Z Med J (1996) 1.42
A neural mechanism for sudden death after myocardial infarction. Clin Auton Res (2003) 1.41
Hemodynamic effects of nitroprusside on valvular aortic stenosis. Am J Cardiol (1992) 1.39
Congenital long QT syndrome in adults. N Z Med J (1989) 1.39
Calorie-restricted weight reduction, blood pressure, and atrial natriuretic peptides. Nutrition (1993) 1.38
Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab (1993) 1.38
Sulindac and cough induced by converting enzyme inhibitors. Lancet (1987) 1.38
Treatment of severe orthostatic hypotension with the somatostatin analogue octreotide. Aust N Z J Med (1990) 1.37
The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun (1995) 1.33
Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab (1994) 1.29
High concentrations of thyroid-stimulating hormone in untreated glucocorticoid deficiency: indication of primary hypothyroidism? Br Med J (Clin Res Ed) (1982) 1.28
Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet (1981) 1.26
Decrease in cardiac output and muscle sympathetic activity during vasovagal syncope. Am J Physiol Heart Circ Physiol (2002) 1.24
Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol (1982) 1.22
Sponsorship, authorship, and accountability. JAMA (2001) 1.22
Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab (1993) 1.21
Hyponatremic-hypertensive syndrome with renal ischemia: an underrecognized disorder. Hypertension (1999) 1.20
Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol (1985) 1.18
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. Br Heart J (1985) 1.18
Haemodynamic effects of atrial peptide infusion in heart failure. Lancet (1986) 1.16
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ (1992) 1.15
Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab (1986) 1.14
Patients presenting with Addison's disease need not be pigmented. Postgrad Med J (1982) 1.13
Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2007) 1.13
Atrial function following cardioversion. Am Heart J (1967) 1.12
An unusual cause of hyperinsulinaemic hypoglycaemia syndrome. Diabet Med (2003) 1.12
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation (1999) 1.12
Natriuretic hormones. Endocrinol Metab Clin North Am (1995) 1.12
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol (1995) 1.11